Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CRMD

CorMedix Q1 2026 Earnings Report

CorMedix logo
$7.73 -0.17 (-2.15%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$7.72 -0.01 (-0.13%)
As of 05/5/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

CorMedix EPS Results

Actual EPS
N/A
Consensus EPS
$0.35
Beat/Miss
N/A
One Year Ago EPS
N/A

CorMedix Revenue Results

Actual Revenue
N/A
Expected Revenue
$104.96 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CorMedix Announcement Details

Quarter
Q1 2026
Date
5/5/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

CorMedix Earnings Headlines

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
May 5 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287682/0/en/cormedix-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-14-2026.html
CRMD stock jumps as antifungal drug clears key trial for $2B preventive market
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/crmd-stock-jumps-as-antifungal-drug-clears-key-trial-for-2b-preventive-market/ar-AA21R9Ao
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.tc pixel
 |  Porter & Company (Ad)
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic ...
April 27, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cormedix-therapeutics-announces-positive-topline-results-from-phase-iii-respect-trial-assessing-rezzayo-for-the-prophylaxis-of-invasive-fungal-diseases-in-allogeneic-hematopoietic-stem-cell-1036065988
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281520/0/en/cormedix-therapeutics-announces-positive-topline-results-from-phase-iii-respect-trial-assessing-rezzayo-for-the-prophylaxis-of-invasive-fungal-diseases-in-allogeneic-hematopoietic-.html
How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets
April 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/cormedix-crmd-story-shifting-lower-110957894.html
See More CorMedix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email.

About CorMedix

CorMedix (NASDAQ:CRMD). is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures. The company is engaged in clinical and regulatory activities designed to support product labeling updates and broader patient access. Collaborative partnerships with dialysis providers and distributors help position CorMedix to deliver its therapies into established treatment settings.

Founded in the mid-2000s and headquartered in Piscataway, New Jersey, CorMedix operates with a lean corporate structure that leverages external manufacturing and distribution networks. The company’s senior management team is led by President and Chief Executive Officer Craig Fraser, who brings more than 30 years of experience in the biopharmaceutical industry. CorMedix continues to pursue regulatory milestones and commercial arrangements that aim to expand its reach across North America, Europe and select emerging markets.

View CorMedix Profile
Earnings Tools